🎉 M&A multiples are live!
Check it out!

Kronos Bio Valuation Multiples

Discover revenue and EBITDA valuation multiples for Kronos Bio and similar public comparables like Vivoryon Therapeutics, Benevolent AI, and Julphar.

Kronos Bio Overview

About Kronos Bio

Kronos Bio Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of small molecule therapeutics to address deregulated transcription, a hallmark of cancer and autoimmune diseases.


Founded

2017

HQ

United States of America
Employees

10

Website

kronosbio.com

Financials

LTM Revenue $9.8M

LTM EBITDA n/a

EV

-$35.2M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Kronos Bio Financials

Kronos Bio has a last 12-month revenue of $9.8M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Kronos Bio achieved revenue of $9.8M and an EBITDA of -$61.7M.

Kronos Bio expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Kronos Bio valuation multiples based on analyst estimates

Kronos Bio P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $6.3M $9.8M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$120M -$61.7M XXX XXX XXX
EBITDA Margin -1904% -627% XXX XXX XXX
Net Profit -$133M -$113M XXX XXX XXX
Net Margin -2118% -1144% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Kronos Bio Stock Performance

As of April 15, 2025, Kronos Bio's stock price is $1.

Kronos Bio has current market cap of $52.3M, and EV of -$35.2M.

See Kronos Bio trading valuation data

Kronos Bio Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$35.2M $52.3M XXX XXX XXX XXX $-1.43

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Kronos Bio Valuation Multiples

As of April 15, 2025, Kronos Bio has market cap of $52.3M and EV of -$35.2M.

Kronos Bio's trades at -3.6x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Kronos Bio's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Kronos Bio and 10K+ public comps

Kronos Bio Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$35.2M XXX XXX XXX
EV/Revenue -3.6x XXX XXX XXX
EV/EBITDA 0.6x XXX XXX XXX
P/E -0.6x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 0.5x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Kronos Bio Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Kronos Bio Valuation Multiples

Kronos Bio's NTM/LTM revenue growth is -100%

Kronos Bio's revenue per employee for the last fiscal year averaged $1.0M, while opex per employee averaged $7.3M for the same period.

Over next 12 months, Kronos Bio's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Kronos Bio's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Kronos Bio and other 10K+ public comps

Kronos Bio Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 57% XXX XXX XXX XXX
EBITDA Margin -627% XXX XXX XXX XXX
EBITDA Growth -48% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee $1.0M XXX XXX XXX XXX
Opex per Employee $7.3M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 250% XXX XXX XXX XXX
R&D Expenses to Revenue 494% XXX XXX XXX XXX
Opex to Revenue 744% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Kronos Bio Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Kronos Bio M&A and Investment Activity

Kronos Bio acquired  XXX companies to date.

Last acquisition by Kronos Bio was  XXXXXXXX, XXXXX XXXXX XXXXXX . Kronos Bio acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Kronos Bio

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Kronos Bio

When was Kronos Bio founded? Kronos Bio was founded in 2017.
Where is Kronos Bio headquartered? Kronos Bio is headquartered in United States of America.
How many employees does Kronos Bio have? As of today, Kronos Bio has 10 employees.
Who is the CEO of Kronos Bio? Kronos Bio's CEO is Dr. Deborah Knobelman, PhD.
Is Kronos Bio publicy listed? Yes, Kronos Bio is a public company listed on NAS.
What is the stock symbol of Kronos Bio? Kronos Bio trades under KRON ticker.
When did Kronos Bio go public? Kronos Bio went public in 2020.
Who are competitors of Kronos Bio? Similar companies to Kronos Bio include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Kronos Bio? Kronos Bio's current market cap is $52.3M
What is the current revenue of Kronos Bio? Kronos Bio's last 12-month revenue is $9.8M.
What is the current EV/Revenue multiple of Kronos Bio? Current revenue multiple of Kronos Bio is -3.6x.
What is the current revenue growth of Kronos Bio? Kronos Bio revenue growth between 2023 and 2024 was 57%.
Is Kronos Bio profitable? Yes, Kronos Bio is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.